Nature Reviews Clinical Oncology, Published online: 08 June 2026; doi:10.1038/s41571-026-01159-6Ciltacabtagene autoleucel (cilta-cel) has transformed the outcomes of patients with relapsed or refractory multiple myeloma, yet its toxicity profile — spanning acute and delayed-onset neurotoxicity, secondary malignancies, immune effector-cell colitis, infections and prolonged cytopenias — has emerged slowly. As safer alternatives become available, the risk–benefit calculus for cilta-cel demands urgent reassessment, particularly in earlier lines of therapy.

Edward Cliff: The ASH25 Lymphoma Roundup Episode is Out / ASH25, cancer, Eddie Cliff, Edward Cliff, lymphoma, OncoDaily, Oncology

This Viewpoint discusses the most favored nation policy vs price negotiation for reducing drug prices.

Education Podcast · 57 Episodes · Updated Semimonthly

This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas.

Key Points. Despite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T-cells have poor outcomes.Future tr

Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and bi...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts and inflict lasting damage on institutional credibility.

As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermine the agency, its workforce, and its mission.

This Viewpoint describes considerations for regulatory oversight in the implementation of artificial intelligence–enabled prognostic devices.

Abstract. The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. Howev

Confirmatory Trials of Accelerated Approval Drugs - Will Imposing Fines Reduce Delays?

Many cancer drugs approved through the FDA's accelerated approval pathway do not offer any survival benefit to patients. In this study, individuals expressed strong preferences for certainty that a ca...